BioForge

Sasol Chemicals and Solugen will evaluate effectiveness of sustainable ingredients in care chemicals applications

Retrieved on: 
Thursday, October 19, 2023
Sustainability, Chemicals, Plastics, Environment, Manufacturing, NYSE, BioForge, SOL, Carbon, Chelation, Detergent, Carbon footprint, SSL, GHG, JSE, Senior, Development

Sasol Chemicals, a business unit of Sasol Ltd. (JSE: SOL; NYSE: SSL), and Solugen today announced an agreement to explore commercialization of new solutions to meet rapidly growing consumer demand for sustainable ingredients in home and personal care products.

Key Points: 
  • Sasol Chemicals, a business unit of Sasol Ltd. (JSE: SOL; NYSE: SSL), and Solugen today announced an agreement to explore commercialization of new solutions to meet rapidly growing consumer demand for sustainable ingredients in home and personal care products.
  • Sasol Chemicals will evaluate the effectiveness of Solugen’s proprietary products, blends and derivatives in its household, personal care, and industrial and institutional cleaning surfactant formulations, initially focusing on chelating agents.
  • “This agreement is an example of our approach of partnering to find innovative solutions for our customers,” said Jonathan Ward, Senior Manager of Strategy and Sustainable Growth for Sasol’s Essential Care Chemicals business division.
  • "We are thrilled to partner with Sasol Chemicals, one of the world’s largest producers of surfactants, to drive positive impact in the home and personal care market,” said Gaurab Chakrabarti, Chief Executive Officer of Solugen.

Global Research and Discovery Group Announces Completion of Research with Impact Biomedical

Retrieved on: 
Tuesday, April 11, 2023
ChromeOS, DiscoverIE Group, Disease, University, Therapy, Potomac Institute for Policy Studies, Patent cliff, Center for Strategic and International Studies, SARS, Biodefense, Research, 3F, COVID, HAVEN, Government, Linebacker, Science, Patent, BioForge, Thompson, Cato Institute, Quantum, Technology transfer, ACE2, Fine chemical, Pharmaceutical industry, Vaccine, Management, Bioplastic

WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.

Key Points: 
  • WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.
  • It is anticipated that the next phase of the research will shift to licensing the Impact Biomedical portfolio to larger pharmaceutical companies for down range development.
  • The end of the active work on this project comes at a key time for Global Research and Discovery, which will shift to identifying potential collaborations for continued research.
  • This becomes an issue since these financial returns are required to support research for newer and more effective biomedical discoveries.

ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation

Retrieved on: 
Thursday, August 25, 2022
Other Manufacturing, Genetics, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Partnership, University, University of Pittsburgh Medical Center, Technology, Wall Street, Pitt, Research, Potency (pharmacology), IPSC, Innovation district, UPMC, Gene editing, Good, Hazelwood (Green Bay, Wisconsin), Regenerative medicine, Trustee, Outline of health sciences, BioForge, Commonwealth, Hazelwood, Science, NIH, Quality of life, National, Student, National Institutes of Health, Foundation, Faculty, CGMP, GMP, Protein engineering, County, LLC, University of Pittsburgh, University of Texas Health Science Center at San Antonio, Ecosystem, Mountaineering, Industry, Drug development, Chancellor, Good manufacturing practice, Patient, Vaccine, Pharmaceutical industry, Management, Coke (fuel)

ElevateBio, LLC (ElevateBio) and the University of Pittsburgh today announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies.

Key Points: 
  • ElevateBio, LLC (ElevateBio) and the University of Pittsburgh today announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies.
  • The Richard King Mellon Foundation announced a $100 million grant to the University of Pittsburgh in November 2021 to create the Pitt BioForge BioManufacturing Center at Hazelwood Green.
  • The University of Pittsburgh and ElevateBio BaseCamp intend to locate the new technology-enabled process development and GMP manufacturing facility at Pitt BioForge at Hazelwood Green to further innovation in the Pittsburgh region.
  • The new facility is expected to generate more than 170 permanent full-time jobs, 900 construction jobs, and 360 off-site support jobs.

University of Pittsburgh, Richard King Mellon Foundation Announce Transformative Gift, Partnership To Make Pittsburgh Region A National Leader In Life Sciences Manufacturing

Retrieved on: 
Wednesday, November 17, 2021
Patient, Richard King Mellon, University, Carnegie Mellon University, Foundation, Trustee, Technology, Industry, Hazelwood (Green Bay, Wisconsin), NIH, Monongahela River, University of Pittsburgh, Neural basis of synesthesia, National Kidney and Transplant Institute, Robotics, Health, Heinz Endowments, UPMC Hillman Cancer Center, Student, University of Pittsburgh School of Medicine, Michigan State University Honors College, Solution, Wall Street, Laboratory, Therapy, Physician, COVID-19, Reimann, Faculty, Financial endowment, Center, School, Research, China Center for Energy and Environmental Policy Research, Knowledge, BioForge, Thomas Starzl, Growth, Translation, UPMC, Hazelwood (Pittsburgh), Pharmaceutical industry, Medicine, Renewable energy, Industrial design

"I am grateful for this support and confident that we'll succeed together in strengthening Southwestern Pennsylvania's role as a leading life sciences destination."

Key Points: 
  • "I am grateful for this support and confident that we'll succeed together in strengthening Southwestern Pennsylvania's role as a leading life sciences destination."
  • Said Richard King Mellon Foundation Director Sam Reiman: "The Foundation is making a historic bet on Pittsburgh to lead nationally in the life sciences.
  • About the University of Pittsburgh: Founded in 1787, the University of Pittsburgh is an internationally renowned leader in health sciences learning and research.
  • About the Richard King Mellon Foundation: Founded in 1947, the Richard King Mellon Foundation is the largest foundation in Southwestern Pennsylvania, and one of the 50 largest in the world.

Solugen Raises Over $350 Million in Series C Funding Led by Baillie Gifford & GIC to Make Carbon Negative Chemicals

Retrieved on: 
Thursday, September 9, 2021

HOUSTON, Texas, Sept. 9, 2021 /PRNewswire/ --Today, Solugen , the company decarbonizing the chemicals industry, announced a Series C financing round of over $350 million.

Key Points: 
  • HOUSTON, Texas, Sept. 9, 2021 /PRNewswire/ --Today, Solugen , the company decarbonizing the chemicals industry, announced a Series C financing round of over $350 million.
  • GIC and Baillie Gifford led the round with participation from Temasek Holdings, funds and accounts managed by BlackRock, Carbon Direct Capital Management, Refactor Capital, and Fifty Years.
  • Solugen's patented Bioforge processes produce chemicals from bio-based feedstocks and are based on breakthroughs in synthetic biology, metal catalyst engineering, and modular plant design.
  • Taken together, this would allow Solugen to decarbonize some of the largest carbon emitting segments of our modern economy.

Solugen Raises Over $350 Million in Series C Funding Led by Baillie Gifford & GIC to Make Carbon Negative Chemicals

Retrieved on: 
Thursday, September 9, 2021

HOUSTON, Texas, Sept. 9, 2021 /PRNewswire/ --Today, Solugen , the company decarbonizing the chemicals industry, announced a Series C financing round of over $350 million.

Key Points: 
  • HOUSTON, Texas, Sept. 9, 2021 /PRNewswire/ --Today, Solugen , the company decarbonizing the chemicals industry, announced a Series C financing round of over $350 million.
  • GIC and Baillie Gifford led the round with participation from Temasek Holdings, funds and accounts managed by BlackRock, Carbon Direct Capital Management, Refactor Capital, and Fifty Years.
  • Solugen's patented Bioforge processes produce chemicals from bio-based feedstocks and are based on breakthroughs in synthetic biology, metal catalyst engineering, and modular plant design.
  • Taken together, this would allow Solugen to decarbonize some of the largest carbon emitting segments of our modern economy.